NEW YORK ─ Partek said Thursday that it has entered into an agreement with Santa Clara, California-based Agilent Technologies to integrate its Partek Flow bioinformatics software with the Agilent Alissa Clinical Informatics platform, providing an end-to-end analysis workflow that is customizable for Agilent's customers.
Financial and other terms of the agreement were not disclosed.
"As next-generation sequencing is more broadly adopted for clinical applications, our customers' software requirements are also expanding," Kevin Meldrum, vice president and general manager of Agilent's Genomics Division, said in a statement. "By integrating Partek Flow with the Agilent Alissa Clinical Informatics Platform, we will strengthen our overall offering to address diverse applications and workflows across the translational research to clinical testing continuum."
With the integration of the bioinformatics software and clinical informatics platform, Partek Flow automatically processes and analyzes data in the background, and then passes results to the Agilent Alissa Interpret platform where the results are combined into a report. The integration enables clinical decision support and the identification of genetic signatures of disease in the clinical setting, as well as secondary analysis and the use of visualization tools for both DNA and RNA applications, Partek said.